ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC
This study also emphasises the importance of molecular biomarker testing in prostate cancer.
Healthcare
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment
Huntington’s gene therapy research has reached a turning point, expert says
Calls for change as access to cell and gene therapies in the Netherlands falls short
Autologous versus allogeneic: how cell therapy development is changing in oncology
SLE and LN market expected to reach $5.9bn across 7MM by 2034
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
Big pharma and investors re-engage in CGTs and race to scale
